Therapy News and Research

RSS

Ventus' PROVENT Sleep Apnea Therapy is runner-up at the The Wall Street Journal Technology Innovation Awards

Ventus Medical, a privately-held medical device company focused on improving the lives of patients with sleep-disordered breathing, today announced that the company's PROVENT(R) Sleep Apnea Therapy received the Runners-Up Award in The Wall Street Journal 2009 Technology Innovation Awards, Medical Devices category. The results were published in the September 14, 2009 edition of The Wall Street Journal.

22 Sep 2009

Mathematical model of an ischemic wound

Scientists expect a new mathematical model of chronic wound healing could replace intuition with clear guidance on how to test treatment strategies in tackling a major public-health problem.

22 Sep 2009

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.

22 Sep 2009

Signaling molecules have different effects on key inhibitory protein

Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.

22 Sep 2009

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

GE Capital deploys $1 billion in the U.S. healthcare market for the first six months of 2009

GE Capital’s Healthcare Financial Services business ended the first six months of 2009 as one of the most active capital providers in the U.S. healthcare market, deploying approximately $1 billion for more than 45 transactions. Loans were used to refinance existing debt, support working capital needs and fund growth initiatives.

21 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

21 Sep 2009

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early stage programme that is intended to deliver products for the treatment of pain without constipation side effects.

21 Sep 2009

Dialysis patient embarks on "Grandpa's Road Trip" with NxStage System One hemodialysis machine

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that home dialysis patient Harvey Wells, 57, has embarked on his third annual "Grandpa's Road Trip" with the NxStage(R) System One(TM). As a portable home hemodialysis machine, the NxStage System One provides Mr. Wells the opportunity to fit hemodialysis therapy into his own lifestyle and schedule. Mr. Wells is once again celebrating this freedom by traveling the country in his RV and sharing with other patients his experience doing home daily hemodialysis with the NxStage System One.

21 Sep 2009

Increasing the half life of proteins to treat diseases such as hepatitis B

Many biopharmaceuticals comprise small proteins that are quickly eliminated from the body. Scientists at the Technische Universitaet Muenchen (TUM) combine such small proteins with a kind of molecular balloon that swells and thus prolongs the half-life of the proteins in the body. The TUM spin-off XL-Protein GmbH has now started to further develop this new technology with blockbuster potential.

21 Sep 2009

Medicaid: Budget gaps, informants, and a plan to expand coverage by going private

States are dealing with their unique Medicaid problems in different ways: New Mexico plans deep cuts, Florida seeks new Medicaid fraud informants, and a California gubernatorial candidate wants to privatize the program in the interest of covering the uninsured.

21 Sep 2009

GI cancer detection simpler and cost-effective with new blood tests

Berlin, Germany: Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin today (Monday September 21). The tests will make GI cancer detection simpler, cost-effective, and more acceptable to patients than current methods, the researchers say.

21 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.

21 Sep 2009

SHP-2 protein molecule encourages placenta growth

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have shown that a common biological protein molecule called SHP-2 is crucial for encouraging placenta growth. The research is published today in Endocrinology.

21 Sep 2009

Therapy News and Research

Ventus' PROVENT Sleep Apnea Therapy is runner-up at the The Wall Street Journal Technology Innovation Awards

Mathematical model of an ischemic wound

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Signaling molecules have different effects on key inhibitory protein

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

MDC scientist receives 1 million euros for diabetic research

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

GE Capital deploys $1 billion in the U.S. healthcare market for the first six months of 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

Swedish researcher to receive Fernström Foundation's Nordic Prize

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

Dialysis patient embarks on "Grandpa's Road Trip" with NxStage System One hemodialysis machine

Increasing the half life of proteins to treat diseases such as hepatitis B

Medicaid: Budget gaps, informants, and a plan to expand coverage by going private

GI cancer detection simpler and cost-effective with new blood tests

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

SHP-2 protein molecule encourages placenta growth

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News